Drugs and Devices

May 2017 Vol. 12 No. 5

On May 5, the U.S. Food and Drug Administration (FDA) approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). Read more . . .

April 2017 Vol. 12 No. 4

On April 27, the U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. It’s the first FDA-approved treatment for a liver cancer in almost a decade . . .

April 2017 Vol. 12 No. 4

Administering medications intranasally as an alternative to I.V.s and injections is becoming more frequent in the ED and out-of-hospital settings, according to a study in Annals of Emergency Medicine. Read more . . .

April 2017 Vol. 12 No. 4

On April 11, the U.S. Food and Drug Administration (FDA) approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. It’s the first drug approved by the FDA for this condition.

The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive . . .

March 2017 Vol. 12 No. 3

On April 7, the U.S. Food and Drug Administration (FDA) approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Read more . . .

March 2017 Vol. 12 No. 3

On April 6, the U.S. Food and Drug Administration (FDA) announced it was allowing marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer genetic tests that the FDA as authorized. Read more . . .

March 2017 Vol. 12 No. 3

On March 28, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema. Read more . . .

March 2017 Vol. 12 No. 3

On March 21, the U.S. Food and Drug Administration (FDA) approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. Read more . . .

March 2017 Vol. 12 No. 3

17-alpha Hydroxyprogesterone caproate, commonly given to prevent recurrent preterm birth, is not effective for prevention and may increase the risk of gestational diabetes, according to a study in the American Journal of Obstetrics & Gynecology. Read more . . .

March 2017 Vol. 12 No. 3

More than half of older women with early stage breast cancer receive more radiation therapy than what might be medically necessary and following evidence-based guidelines for radiation would significantly reduce costs, according to a study in the Journal of Oncology Practice. Read more . . .